NCT04999800

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

A Prospective Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Combined With Anlotinib in First-line Treatment for Patients With of R/M HNSCC PD-L1 CPS≥1

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shi Yuankai · Unknown
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1

Detailed description

This test is a single-center, prospective phase II clinical research, plan included in 20 cases of eligible subjects, assessment in China PD-L1 CPS≥1 or more recurrent and/or metastatic head and neck squamous cell carcinoma patients, Pembrolizumab combined with Anlotinib for the initial curative effect, adverse reaction and safety, provide the basis for subsequent clinical trials

Conditions

• Head and Neck Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
DRUG	Anlotinib	Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor

Timeline

• Start date: 2021-07-18
• Primary completion: 2023-01-01
• Completion: 2024-06-30
• First posted: 2021-08-11
• Last updated: 2021-08-11

Locations

1 site across 1 country: China